EichorEICHOR
Condition: Phase Ib Synced from ClinicalTrials.gov · August 05, 2026

Recruiting studies: Phase Ib

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
Phase 1/Phase 2 · 4 location(s) · Genfleet Therapeutics (Shanghai) Inc. · NCT07259590Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemi
NA · 8 location(s) · M.D. Anderson Cancer Center · NCT02945579A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Phase 1/Phase 2 · 7 location(s) · Nanjing Leads Biolabs Co.,Ltd · NCT07281976A Study of AK129 in Patients With Advanced Malignant Tumors
Phase 1 · 1 location(s) · Akeso · NCT05645276A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Ref
Phase 1 · 5 location(s) · Hoffmann-La Roche · NCT06934044Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia
Phase 1 · 1 location(s) · Seoul National University Hospital · NCT05210907Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Phase 1 · 18 location(s) · Duke Street Bio Ltd · NCT06458712Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Phase 1/Phase 2 · 9 location(s) · Sichuan Enray Pharmaceutical Sciences Company · NCT07433283Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
Phase 2 · 3 location(s) · City of Hope Medical Center · NCT04930653The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma
Phase 1/Phase 2 · 1 location(s) · Fudan University · NCT05774275Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NI
Phase 1 · 52 location(s) · National Cancer Institute (NCI) · NCT03816345A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Phase 1/Phase 2 · 1 location(s) · Forward Pharmaceuticals Co., Ltd. · NCT07002177Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Phase 1 · 9 location(s) · Ascentage Pharma Group Inc. · NCT04260022Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
Phase 1/Phase 2 · 1 location(s) · Fudan University · NCT06718933Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT05640609A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
Phase 1 · 8 location(s) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · NCT06615193Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma
Phase 2 · 1 location(s) · Samsung Medical Center · NCT05528458A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locall
Phase 1/Phase 2 · 2 location(s) · Asan Medical Center · NCT06732856Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
Phase 1 · 1 location(s) · Jiangsu Alphamab Biopharmaceuticals Co., Ltd · NCT06868732Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT07047885PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1 · 6 location(s) · PanTher Therapeutics · NCT06673017Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT04780568A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab a
Phase 1 · 31 location(s) · Hoffmann-La Roche · NCT05091424Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma
Phase 1/Phase 2 · 4 location(s) · Instituto Oncológico Dr Rosell · NCT07251413A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Othe
Phase 1/Phase 2 · 71 location(s) · Hoffmann-La Roche · NCT05789082Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for
Phase 1/Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06454448Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
Phase 1/Phase 2 · 1 location(s) · Jiangsu Alphamab Biopharmaceuticals Co., Ltd · NCT06942234A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung
Phase 1/Phase 2 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT05482568A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
Phase 1/Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05803018A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Phase 1/Phase 2 · 21 location(s) · Alliance Foundation Trials, LLC. · NCT04486352
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.